-+ 0.00%
-+ 0.00%
-+ 0.00%

Palatin Technologies Reports 71% Of Patients Achieved >30% UP/Cr Reduction In Phase 2b Diabetic Kidney Study

Benzinga·04/10/2025 11:44:45
Listen to the news
  • Six-month open-label study showed clinically meaningful improvements in kidney function and disease in patients with Type 2 diabetic nephropathy.
    • 71% achieved a >30% reduction in UP/Cr, a key indicator of kidney damage.
    • 71% demonstrated improved or stabilized eGFR, signaling preserved kidney function.
    • 37.5% had increased urinary VEGF levels, suggesting better blood vessel support in the kidneys.
    • 36% had reduced urinary synaptopodin losses, indicating healthier kidney cells and structure.